Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
103.86
+7.27 (7.53%)
At close: Nov 6, 2026, 4:00 PM EST
103.00
-0.86 (-0.83%)
After-hours: Nov 6, 2026, 7:30 PM EST

Spyre Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
---0.892.3318.74
Revenue Growth
----61.96%-87.57%-
Cost of Revenue
259.72171.65162.7984.0558.5857.07
Gross Profit
-259.72-171.65-162.79-83.16-56.25-38.33
Selling, General & Admin
60.4547.9145.7834.4528.5327.32
Operating Expenses
60.4547.9145.7834.4528.5327.32
Operating Income
-320.17-219.56-208.57-117.61-84.78-65.65
Interest & Investment Income
34.8124.8921.316.150.840.11
Other Non Operating Income (Expenses)
-48.529.46-20.71-102.66-0.01-0.12
EBT Excluding Unusual Items
-333.86-165.22-207.97-214.13-83.95-65.66
Merger & Restructuring Charges
----10.95--
Gain (Loss) on Sale of Assets
7010-16.45--
Pretax Income
-263.86-155.22-207.97-338.82-83.95-65.66
Income Tax Expense
--0.020.05-0.03-0.140.14
Net Income
-263.86-155.2-208.02-338.79-83.82-65.8
Preferred Dividends & Other Adjustments
-39.85-28.66-58.46-243.91--
Net Income to Common
-224.01-126.54-149.56-94.88-83.82-65.8
Net Income Growth
------
Shares Outstanding (Basic)
826447733
Shares Outstanding (Diluted)
826447733
Shares Change
38.78%36.21%581.85%104.59%28.19%23.18%
EPS (Basic)
-2.73-1.98-3.18-13.76-24.86-25.02
EPS (Diluted)
-2.73-1.98-3.18-13.76-24.86-25.02
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-249.32-169.25-157.41-99.91-80.18-54.29
Free Cash Flow Per Share
-3.04-2.64-3.35-14.49-23.78-20.64
Gross Margin
------204.55%
Operating Margin
----13274.49%-3640.23%-350.33%
Profit Margin
----10709.14%-3598.76%-351.14%
Free Cash Flow Margin
----11276.52%-3442.76%-289.71%
EBITDA
---207.82-116.87-83.21-64.07
D&A For EBITDA
--0.740.741.571.58
EBIT
-320.17-219.56-208.57-117.61-84.78-65.65
Revenue as Reported
---0.892.3318.74
SEC Filings: 10-K · 10-Q